Daniel O. Wilds

DANIEL O. WILDS was appointed President and Chief Executive Officer and
a Director of Scolr, Inc., in August 2003. From 1998 to July 2003, Mr.
Wilds served as Chairman, President and CEO of Northwest
Biotherapeutics, Inc. Prior to that position, he was President and CEO
of Shiloov Biotechnologies (USA), Inc. from 1997 to 1998. From 1992 to
1996, Mr. Wilds was President and CEO of Adeza Biomedical Corporation,
prior to which he served as the President and CEO of Medisense, Inc. and
President of Baxter’s Chemotherapy Service. Mr. Wilds has also served as
President and COO of Travenol-Genentech, Inc., a joint venture between
Baxter International and Genentech, Inc., and has held other domestic
and international senior management positions in the biomedical and
biopharmaceutical fields. Mr. Wilds currently serves on the Board of
Helix BioMedix, Inc. and is a member of the Leadership Council for the
Albert B. Sabine Vaccine Institute’s Cancer Vaccine Consortium. Mr.
Wilds holds a BA from California State University, Los Angeles and an
MBA from Northwestern University.